| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA4394735 | A | Clearance in C57BL/6 mouse at 1 mg/kg, iv or 10 mg/kg, po administered via gavage by HPLC-MS/MS analysis | Mus musculus | 5 | organism-based format | Scientific Literature | ||
| 2. | ALA4394736 | B | Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-yl)methyl)amino)-6-oxohexyl)-3,3-dimethyl-5-sulfoindolin-2-ylidene)penta-1,3-dien-1-yl)-1-ethyl-3,3-dimethyl-5-sulfo-3H-indol-1-ium binding to biotin-labeled recombinant human FD expressed in Escherichia coli measured after 2 hrs by TR-FRET assay | Homo sapiens | 17 | assay format | Scientific Literature | ||
| 3. | ALA4394738 | A | Oral bioavailability in C57BL/6 mouse 10 mg/kg by HPLC-MS/MS analysis | Mus musculus | 5 | organism-based format | Scientific Literature | ||
| 4. | ALA4394739 | B | Selectivity ratio of IC50 for tryptase-beta2 (unknown origin) to IC50 for inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-yl)methyl)amino)-6-oxohexyl)-3,3-dimethyl-5-sulfoindolin-2-ylidene)penta-1,3-dien-1-yl)-1-ethyl-3,3-dimethyl-5-sulfo-3H-indol-1-ium binding to biotin-labeled recombinant human FD expressed in Escherichia coli | Homo sapiens | 6 | assay format | Scientific Literature | ||
| 5. | ALA4394740 | B | Selectivity ratio of IC50 for F11a (unknown origin) to IC50 for inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-yl)methyl)amino)-6-oxohexyl)-3,3-dimethyl-5-sulfoindolin-2-ylidene)penta-1,3-dien-1-yl)-1-ethyl-3,3-dimethyl-5-sulfo-3H-indol-1-ium binding to biotin-labeled recombinant human FD expressed in Escherichia coli | Homo sapiens | 6 | assay format | Scientific Literature | ||
| 6. | ALA4394741 | B | Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack complex formation preincubated for 15 mins followed by zymosan stimulation and measured after 40 mins by ELISA | Homo sapiens | 17 | tissue-based format | Scientific Literature | ||
| 7. | ALA4394742 | A | Apparent permeability of the compound by PAMPA | 17 | assay format | Scientific Literature | |||
| 8. | ALA4394743 | B | Inhibition of F11a (unknown origin) | Homo sapiens | 10 | single protein format | Scientific Literature | ||
| 9. | ALA4394744 | B | Inhibition of tryptase-beta2 (unknown origin) | Homo sapiens | 10 | single protein format | Scientific Literature | ||
| 10. | ALA4394745 | B | Inhibition of urokinase (unknown origin) | Homo sapiens | 2 | single protein format | Scientific Literature | ||
| 11. | ALA4394746 | B | Selectivity ratio of IC50 for urokinase (unknown origin) to IC50 for inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-yl)methyl)amino)-6-oxohexyl)-3,3-dimethyl-5-sulfoindolin-2-ylidene)penta-1,3-dien-1-yl)-1-ethyl-3,3-dimethyl-5-sulfo-3H-indol-1-ium binding to biotin-labeled recombinant human FD expressed in Escherichia coli | Homo sapiens | 2 | assay format | Scientific Literature | ||
| 12. | ALA4394747 | A | Cmax in C57BL/6 mouse at 10 mg/kg, po administered via gavage by HPLC-MS/MS analysis | Mus musculus | 3 | organism-based format | Scientific Literature | ||
| 13. | ALA4394748 | A | AUC (0 to 7 hrs) in C57BL/6 mouse at 1 mg/kg, iv by HPLC-MS/MS analysis | Mus musculus | 3 | organism-based format | Scientific Literature | ||
| 14. | ALA4394749 | A | Volume of distribution at steady state in C57BL/6 mouse at 1 mg/kg, iv or 10 mg/kg, po administered via gavage by HPLC-MS/MS analysis | Mus musculus | 3 | organism-based format | Scientific Literature | ||
| 15. | ALA4394750 | A | Elimination half life in C57BL/6 mouse at 1 mg/kg, iv by HPLC-MS/MS analysis | Mus musculus | 3 | organism-based format | Scientific Literature | ||
| 16. | ALA4394751 | F | Suppression of LPS-induced alternative complementation pathway in human FD knock-in C57BL/6 mouse assessed as reduction in plasma Ba level treated via oral gavage 3.5 hrs prior to LPS stimulation and measured up to 24 hrs post-dose | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 17. | ALA4394752 | A | AUC (0 to 7 hrs) in C57BL/6 mouse at 10 mg/kg, po administered via gavage by HPLC-MS/MS analysis | Mus musculus | 3 | organism-based format | Scientific Literature | ||
| 18. | ALA4394753 | A | Dose normalized AUC in Brown Norway rat plasma at 10 mg/kg, po administered via gavage by HPLC-MS/MS analysis | Rattus norvegicus | 1 | organism-based format | Scientific Literature | ||
| 19. | ALA4394754 | A | Dose normalized AUC in Brown Norway rat posterior eye cup at 10 mg/kg, po administered via gavage by HPLC-MS/MS analysis | Rattus norvegicus | 1 | organism-based format | Scientific Literature | ||
| 20. | ALA4394755 | A | Dose normalized AUC in Brown Norway rat retina at 10 mg/kg, po administered via gavage by HPLC-MS/MS analysis | Rattus norvegicus | 1 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!